49 related articles for article (PubMed ID: 21033470)
1. [Glutoxime--an inhibitor of multiple drug resistance phenotype associated with Pgp expression].
Bogush TA; Dudko EA; Bogush EA; Kirsanov VIu; Antonov VG
Antibiot Khimioter; 2010; 55(5-6):18-23. PubMed ID: 21033470
[TBL] [Abstract][Full Text] [Related]
2. H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein.
Wei N; Sun H; Wang F; Liu G
Cancer Chemother Pharmacol; 2011 May; 67(5):1017-25. PubMed ID: 20640574
[TBL] [Abstract][Full Text] [Related]
3. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
4. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells.
Shen F; Chu S; Bence AK; Bailey B; Xue X; Erickson PA; Montrose MH; Beck WT; Erickson LC
J Pharmacol Exp Ther; 2008 Jan; 324(1):95-102. PubMed ID: 17947497
[TBL] [Abstract][Full Text] [Related]
6. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.
Riganti C; Voena C; Kopecka J; Corsetto PA; Montorfano G; Enrico E; Costamagna C; Rizzo AM; Ghigo D; Bosia A
Mol Pharm; 2011 Jun; 8(3):683-700. PubMed ID: 21491921
[TBL] [Abstract][Full Text] [Related]
7. [Parameters of specific antibody interaction with P-gp in T-cell leukemia Jurkat cells].
Bogush TA; Dudko EA; Bogush EA; Baryshnikov AIu
Antibiot Khimioter; 2009; 54(1-2):3-9. PubMed ID: 19499709
[TBL] [Abstract][Full Text] [Related]
8. Immunization with liposome-anchored pegylated peptides modulates doxorubicin sensitivity in P-glycoprotein-expressing P388 cells.
Gatouillat G; Odot J; Balasse E; Nicolau C; Tosi PF; Hickman DT; López-Deber MP; Madoulet C
Cancer Lett; 2007 Nov; 257(2):165-71. PubMed ID: 17517470
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of P-glycoprotein-mediated transport by S-adenosylmethionine and cynarin in multidrug-resistant human uterine sarcoma MES-SA/Dx5 cells.
Angelini A; Di Pietro R; Centurione L; Castellani ML; Conti P; Porreca E; Cuccurullo F
J Biol Regul Homeost Agents; 2012; 26(3):495-504. PubMed ID: 23034269
[TBL] [Abstract][Full Text] [Related]
10. Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy.
Angelini A; Di Ilio C; Castellani ML; Conti P; Cuccurullo F
J Biol Regul Homeost Agents; 2010; 24(2):197-205. PubMed ID: 20487633
[TBL] [Abstract][Full Text] [Related]
11. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells.
Sonneveld P; Schoester M; de Leeuw K
J Clin Oncol; 1994 Aug; 12(8):1584-91. PubMed ID: 7518859
[TBL] [Abstract][Full Text] [Related]
12. Glucose modulation induces reactive oxygen species and increases P-glycoprotein-mediated multidrug resistance to chemotherapeutics.
Seebacher NA; Richardson DR; Jansson PJ
Br J Pharmacol; 2015 May; 172(10):2557-72. PubMed ID: 25586174
[TBL] [Abstract][Full Text] [Related]
13. Pyronaridine, a novel modulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo.
Qi J; Wang S; Liu G; Peng H; Wang J; Zhu Z; Yang C
Biochem Biophys Res Commun; 2004 Jul; 319(4):1124-31. PubMed ID: 15194484
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.
Kitazaki T; Oka M; Nakamura Y; Tsurutani J; Doi S; Yasunaga M; Takemura M; Yabuuchi H; Soda H; Kohno S
Lung Cancer; 2005 Sep; 49(3):337-43. PubMed ID: 15955594
[TBL] [Abstract][Full Text] [Related]
15. Redox regulation of P-glycoprotein-mediated multidrug resistance in multicellular prostate tumor spheroids.
Wartenberg M; Fischer K; Hescheler J; Sauer H
Int J Cancer; 2000 Jan; 85(2):267-74. PubMed ID: 10629088
[TBL] [Abstract][Full Text] [Related]
16. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
[TBL] [Abstract][Full Text] [Related]
17. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes.
van Ark-Otte J; Samelis G; Rubio G; Lopez Saez JB; Pinedo HM; Giaccone G
Oncol Rep; 1998; 5(1):249-55. PubMed ID: 9458331
[TBL] [Abstract][Full Text] [Related]
18. ANTIPSYCHOTICS REVERSE P-GLYCOPROTEIN-MEDIATED DOXORUBICIN RESISTANCE IN HUMAN UTERINE SARCOMA MES-SA/Dx5 CELLS: A NOVEL APPROACH TO CANCER CHEMOTHERAPY.
Angelini A; Ciofani G; Conti P
J Biol Regul Homeost Agents; 2015; 29(2):357-65. PubMed ID: 26122223
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells.
Nadali F; Pourfathollah AA; Alimoghaddam K; Nikougoftar M; Rostami S; Dizaji A; Azizi E; Zomorodipour A; Ghavamzadeh A
Hematology; 2007 Oct; 12(5):393-401. PubMed ID: 17852455
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function.
Elamanchili P; McEachern C; Burt H
J Pharm Sci; 2009 Mar; 98(3):945-58. PubMed ID: 18623213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
